MIRVASO Gel Ref.[6613] Active ingredients: Brimonidine

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Galderma International, Tour Europlaza, 20 avenue André Prothin – La Défense 4, La Défense Cedex 92927, France

Product name and form

Mirvaso 3 mg/g gel.

Pharmaceutical Form

Gel.

White to light yellow opaque aqueous gel.

Qualitative and quantitative composition

One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.

Excipient(s) with known effect: One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol (E1520).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Brimonidine

Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.
List of Excipients

Carbomer
Methylparahydroxybenzoate (E218)
Phenoxyethanol
Glycerol
Titanium dioxide
Propylene glycol (E1520)
Sodium hydroxide
Purified water

Pack sizes and marketing

Tube of 2g:

Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polyethylene (PE) child resistant closure

Tube of 10 g and 30g:

Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.

And

Polyethylene (PE)/ Polyethylene (PE)/Copolymer/Aluminium (Al)/Polyethylene (PE)/Polyethylene high density (PEHD) and Linear low density polyethylene (LLDPE) polyfoil tubes with polypropylene (PP) child resistant closure.

Pump of 30 g:

Multidose container with airless pump system with child resistant closure.

Polypropylene (PP)/Thermoplastic Polyolefin (TPO)/high density polyethylene (HDPE) and polypropylene (PP) child resistant closure.

Pack sizes: 1 tube of 2 g,10 g or 30 g; 1 pump of 30 g.

Not all pack sizes may be marketed.

Marketing authorization holder

Galderma International, Tour Europlaza, 20 avenue André Prothin – La Défense 4, La Défense Cedex 92927, France

Marketing authorization dates and numbers

Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes:

EU/1/13/904/004
EU/1/13/904/005
EU/1/13/904/006

Polyethylene (PE)/ Polyethylene (PE)/Copolymer/Aluminium (Al)/Polyethylene (PE)/Polyethylene high density (PEHD) and Linear low density polyethylene (LLDPE) polyfoil tubes:

EU/1/13/904/008
EU/1/13/904/009

Polypropylene (PP)/Thermoplastic Polyolefin (TPO)/high density polyethylene (HDPE) and polypropylene (PP) child resistant closure:

EU/1/13/904/007

Date of first authorisation: 21 February 2014
Date of latest renewal: 22 November 2018

Drugs

Drug Countries
MIRVASO Austria, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States
 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈